Back to Search
Start Over
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
- Source :
- Future oncology (London, England). 18(29)
- Publication Year :
- 2022
-
Abstract
- Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with ≥2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting. Clinical Trial Registration: NCT03306394 ( ClinicalTrials.gov )
Details
- ISSN :
- 17448301
- Volume :
- 18
- Issue :
- 29
- Database :
- OpenAIRE
- Journal :
- Future oncology (London, England)
- Accession number :
- edsair.doi.dedup.....fd86188dbfdccc12994176e17b3c817f